Video Interview: F-star CEO Details Asset-Centric Ambitions
This article was originally published in Scrip
Executive Summary
Unveiling its second asset-centric deal, F-star CEO Dr. John Haurum reveals to Mike Ward, global director of content for Informa's pharma insights products, how the company is looking to raise an additional $30m this year to help the company move some of its own programs into the clinic within 18 months. Dr. Haurum describes differences in the deals involving F-star alpha, an option deal with Bristol-Myers Squibb, and F-star beta which will see AbbVie get access to assets that will allow it to create bispecific antibodies targeting two particular immuno-oncology checkpoints.
You may also be interested in...
Denali Deal & F-star’s Innovative Asset Centric Business Model
Jane Dancer, chief business officer at F-star – a Cambridge, UK-based biotech – chats to Mike Ward, global director of content for Informa Pharma Intelligence, on the sidelines of the recent BIO-Europe partnering conference in Cologne, Germany.
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.